About this trial
This study was a single-arm, open-label, "3 + 3" dose-escalation Exploratory research. The patients were divided into two groups: EBV TCR-T-cell Group and EBV CAR-T-cell group. The EBV CAR-T-treated group received three progressively increasing dose levels (3.0 × 106 cells/kg, 9.0 × 106 cells/kg, 1.5 × 107 cells/kg) of EBV CAR-T-cell therapy; The EBV TCR-T-cell group received three progressively increasing doses (5.0 × 106 cells/kg, 1.5 × 107 cells/kg, 3.0 × 107 cells/kg) of EBV TCR-T-cell therapy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Voluntary written informed consent;
Age ≥18 years old, ≤75 years old, male and female;
Expected survival ≥3 months;
The Eastern Cooperative Oncology Group (ECOG) physical fitness score was 0-2;
Disqualifiers
Active central nervous system metastases (except those that are stable after treatment);
HIV positive, HBsAg positive and HBV DNA copy number positive (quantitative detection ≥1000 CPS/ml) , HCV antibody positive and HCV RNA positive;
Patients with mental or psychological disorders who can not cooperate with the treatment and evaluation of the curative effect;
Subjects with severe autoimmune disease and long-term use of immunosuppressants;
Trial design
Parallel
Treatments tested in this trial
PK Blood Collection
BehavioralAll subjects were subjected to PK blood sampling as prescribed by the protocol.
CAR
DrugTarget A positive subjects will receive CAR-T cell therapy.
TCR
DrugTarget A negative, Target B positive and Target C positive subjects will receive TCR-T cell therapy.
Treatment groups
Trial outcomes
Primary outcomes
Dose Limiting Toxicities
Analysis based on clinical trial data of subjects
MTD or the best effective dose
Analysis based on clinical trial data of subjects
Incidence of AE、SAE、AESI
Analysis based on clinical trial data of subjects
Secondary outcomes
PK parameter:Cmax
Analysis based on clinical trial data of subjects
PK parameter:Tmax
Analysis based on clinical trial data of subjects
ORR
Analysis based on clinical trial data of subjects
DCR
Analysis based on clinical trial data of subjects
Sponsors and contacts
Click on the lead sponsor to view all of their trials.